Subscribe
Home
Issues
Online First
2023
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Issues
2016 Issues
July Vol 9 No 4
TON July 2016 Vol 9 No 4
Putting Patients First at Fairfield Medical Center
Cancer Center Profile
TON July 2016 Vol 9 No 4
Fairfield Medical Center in Lancaster, OH, is a comprehensive cancer care program where medical oncologists, radiation oncologists, surgeons, oncology nurses, and other team members work together to provide an individualized treatment plan for every patient.
Read More ›
How to Assess Quality in the Age of Precision Medicine
By
Meg Barbor, MPH
Conference Correspondent
TON July 2016 Vol 9 No 4
Even though many patients have profound responses to targeted therapy, they can often develop resistance, and this can happen quickly.
Read More ›
“Newer” Ovarian Cancer Genes, Option of Risk-Reducing Salpingo-Oophorectomy
By
Cristi Radford, MS, CGC
Genetic Counseling
TON July 2016 Vol 9 No 4
The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer-predisposing gene.
Read More ›
Diagnostic Imaging Agent FDA Approved for Rare Neuroendocrine Tumors
FDA Updates
TON July 2016 Vol 9 No 4
Diagnostic Imaging Agent FDA Approved for Rare Neuroendocrine Tumors
Diagnostic Blood Test FDA Approved for NSCLC Gene Mutation
Axumin FDA Approved for Recurrent Prostate Cancer
Read More ›
From the Editor
By
Beth Faiman, PhD, APRN-BC, AOCN
From the Editor
TON July 2016 Vol 9 No 4
We hope you enjoy this issue, and sincerely look forward to receiving your feedback.
Read More ›
Molecular Profiling Is Vital in Patients with Metastatic Cancer
By
Meg Barbor, MPH
Conference Correspondent
TON July 2016 Vol 9 No 4
Physicians need to advocate for molecular profiling, according to Howard "Skip" Burris III, MD.
Read More ›
Electronic “Facility Board” Provides Easy Look at Patient Status
By
Caroline Helwick
Conference Correspondent
TON July 2016 Vol 9 No 4
An electronic "facility board" situated on a wall in the nurses station of a medical/surgical unit led to more clinical interventions for abnormal vital signs, a reduction in falls among high-risk patients, and more ordering of specialty beds, according to nurses from Cancer Treatment Centers of America (CTCA) at Eastern Regional Medical Center in Philadelphia, PA.
Read More ›
Opioid Prescriptions for Pain Management: Safe Patient, Prescriber, Community
By
Wayne Kuznar
Conference Correspondent
TON July 2016 Vol 9 No 4
Achieving balance in the appropriate use of opioids to treat cancer pain requires skill and compassion.
Read More ›
Palliative Care Specialists Want More Involvement
By
Audrey Andrews
Conference Correspondent
TON July 2016 Vol 9 No 4
When patients hear the phrase
palliative care
, they sometimes feel their oncology team is "giving up on them," according to a survey of attendees at the National Comprehensive Cancer Network (NCCN) 21st Annual Conference.
Read More ›
The Benefits of Triage and the COME HOME Model
By
Meg Barbor, MPH
Conference Correspondent
TON July 2016 Vol 9 No 4
At the heart of the oncology medical home is triage, according to Barbara McAneny, MD, Chief Executive Officer of New Mexico Cancer Center as well as Innovative Oncology Business Solutions (IOBS), where she also serves as chief medical officer.
Read More ›
Page 1 of 3
1
2
3
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION